

Xiao Zang, Ph.D.

Assistant Professor

Division of Health Policy and Management | School of Public Health | University of Minnesota

Email: xzang@umn.edu

Research Area

Health policy; Health services research; Health equity; Economic evaluation; Decision analytical modeling; Quasi-experimental analysis; Infectious diseases; Opioid overdose prevention

Education

Doctor of Philosophy, Health Sciences Simon Fraser University (SFU), Burnaby, British Columbia, Canada	2020
Master of Science, Industrial and Systems Engineering Graduate Certificate in Optimization and Supply Chain Management University of Southern California (USC), Los Angeles, California, USA	2015
Bachelor of Engineering, Transportation Engineering Southeast University (SEU), Nanjing, Jiangsu, China	2013

Postdoctoral Training

Postdoctoral Research Associate Department of Epidemiology Brown University, School of Public Health	03/2020–10/2022 Providence, RI
---	-----------------------------------

Peer-reviewed Publications

- Zang X**, Bessey SE, Krieger MS, Hallowell BD, Koziol JA, Nolen S, Behrends CN, Murphy SM, Walley AY, Linas BP, Schackman BR, Marshall BDL. Comparing projected fatal overdose outcomes and costs of strategies to expand community-based distribution of naloxone in Rhode Island. *JAMA Network Open*. IN PRESS.
- Nolen S, **Zang X**, Chatterjee A, Behrends CN, Green TC, Linas BP, Morgan JR, Murphy SM, Walley AY, Schackman BR, Marshall BD. Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts. *Drug and Alcohol Dependence*. 2022 Oct 20;109668.
- Jacka BP, Nolan S, Bessey S, **Zang X**, Goedel WC, Yedinak J, Marshall BD. Use of pre-exposure prophylaxis (PrEP) to prevent rapid HIV transmission among people who inject drugs (PWID) in rural counties in the United States: A modelling study. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. September 23, 2022.
- Jiang S, Wang Y, Si L, **Zang X**, Gu Y, Jiang Y, Liu GG, Wu J. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide, and a research agenda for China. *BMJ Global Health*. 2022;7:e009777.
- Chambers LC, Hallowell BD, **Zang X**, Rind DM, Guzauskas GF, Hansen RN, Fuchs N, Scagos RP, Marshall BD. The Estimated Costs and Benefits of a Hypothetical Supervised Consumption Site in Providence, Rhode Island. *International Journal of Drug Policy*. 2022 Oct 1;108:103820.
- Nosyk B, **Zang X**, Krebs E. Letter to the Editor RE: Wheatley et al. “Cost-Effectiveness of Interventions to

Improve HIV Pre-Exposure Prophylaxis Initiation, Adherence, and Persistence among Men Who Have Sex with Men. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2022 May 13:10-97.

7. **Zang X**, Goedel WC, Bessey SE, Lurie MN, Galea S, Galvani AP, Friedman SR, Nosyk B, Marshall BD. The impact of rural syringe services program closure on the risk of rebound HIV outbreaks among people who inject drugs: A modeling study. *AIDS*. 2022 May 1;36(6):881-8.
8. Nolen S, **Zang X**, Chatterjee A, Behrends CN, Green TC, Kumar A, Linas BP, Morgan JR, Murphy SM, Walley AY, Yan S, Schackman BR, Marshall BD. Naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. *Addiction*. 2022 May 1;117(5):1372-81.
9. **Zang X**, Mah C, Quan AML, Min JE, Armstrong WS, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Kirk GD, Marshall BD, Mehta SH, Metsch LR, Pandya A, Schackman BR, Shoptaw S, Strathdee SA, Krebs E, Nosyk B. Human Immunodeficiency Virus transmission by ethnicity, HIV risk group and engagement in the care continuum: A contrast of six US cities. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2022 Feb 1;89(2):143-50.
10. Shi W, Cheng X, Wang H, **Zang X**, Chen T. The cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modeling studies. *BMJ Open*. 2021;11:e052682.
11. **Zang X**, Macmadu A, Krieger MS, Behrends CN, Green TC, Morgan JR, Murphy SM, Nolen S, Walley AY, Schackman BR, Marshall BD. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. *International Journal of Drug Policy*. 2021 Dec 1;98:103435.
12. Quan AM, Mah C, Krebs E, **Zang X**, Chen S, Althoff K, Armstrong W, Behrends CN, Dombrowski JC, Enns E, Feaster DJ. Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities. *The Lancet HIV*. 2021 Sep 1;8(9):e581-90.
13. Krebs E, Enns E, **Zang X**, Mah CS, Quan AM, Behrends CN, Coljin C, Goedel W, Golden M, Marshall BD, Metsch LR. Attributing health benefits to preventing HIV infections versus improving health outcomes among people living with HIV: an analysis in six US cities. *AIDS*. 2021 Nov 1;35(13):2169-79.
14. Hongdilokkul N, Krebs E, **Zang X**, Zhou H, Homayra F, Min JE, Nosyk B. The effect of British Columbia's Pharmacare coverage expansion for opioid agonist treatment. *Health Economics*. 2021 May;30(5):1222-38.
15. Shao T, Li X, Zhou C, **Zang X**, Malone DC, Zhang L, Zhou J, Tang W. Effectiveness and efficiency of non-drug therapy among community-dwelling adults with hypertension in China: A protocol for network meta-analysis and cost-Effectiveness analysis. *Frontiers in medicine*. 2021 Feb 25;8:192.
16. Singleton AL, Marshall BD, **Zang X**, Nunn AS, Goedel WC. Added benefits of pre-exposure prophylaxis use on HIV incidence with minimal changes in efficiency in the context of high treatment engagement among men who have sex with men. *AIDS Patient Care and STDs*. 2020 Dec 1;34(12):506-15.
17. **Zang X**, Krebs E, Chen S, Piske M, Armstrong WS, Behrends CN, Del Rio C, Feaster DJ, Marshall BD, Mehta SH, Mermin J. The potential epidemiological impact of coronavirus disease 2019 (COVID-19) on the human immunodeficiency virus (HIV) epidemic and the cost-effectiveness of linked, opt-out HIV testing: A modeling study in 6 US cities. *Clinical Infectious Diseases*. 2021 Jun 1;72(11):e828-34.
18. **Zang X**, Jalal H, Krebs E, Pandya A, Zhou H, Enns B, Nosyk B. Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. *Value in Health*. 2020 Dec 1;23(12):1534-42.
19. Krebs E, **Zang X**, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Gebo KA, Marshall BD, Mehta SH. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. *The Journal of Infectious Diseases*. 2020 Oct 1;222(Supplement_5):S301-11.

20. **Zang X**, Krebs E, Mah C, Min JE, Marshall BD, Feaster DJ, Schackman BR, Metsch LR, Strathdee SA, Behrends CN, Nosyk B. Can the 'Ending the HIV Epidemic' initiative transition the USA towards HIV/AIDS epidemic control?. *AIDS*. 2020 Dec 1;34(15):2325-8.
21. Nosyk B, Weiner J, Krebs E, **Zang X**, Enns B, Behrends CN, Feaster DJ, Jalal H, Marshall BD, Pandya A, Schackman BR. Dissemination science to advance the use simulation modeling: Our obligation moving forward. *Medical Decision Making*. 2020 Aug;40(6):718-21.
22. Jiang S, Chen Z, **Zang X**, Wu J, Jiang Y. Addressing methodological and ethical issues in practicing health economic evaluation in China. *Journal of global health*. 2020 Dec;10(2).
23. Nosyk B, Krebs E, **Zang X**, Piske M, Enns B, Min JE, Behrends CN, Del Rio C, Feaster DJ, Golden M, Marshall BD. 'Ending the Epidemic' will not happen without addressing racial/ethnic disparities in the US HIV epidemic. *Clinical Infectious Diseases*. 2020 Dec 1;71(11):2968-71.
24. Nosyk B, **Zang X**, Krebs E, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Golden M, Marshall BD. Ending the HIV epidemic in the USA: an economic modelling study in six cities. *The Lancet HIV*. 2020 Jul 1;7(7):e491-503.
25. **Zang X**, Krebs E, Min JE, Pandya A, Marshall BD, Schackman BR, Behrends CN, Feaster DJ, Nosyk B. Development and calibration of a dynamic HIV transmission model for 6 US cities. *Medical Decision Making*. 2020 Jan;40(1):3-16.
26. Krebs E, **Zang X**, Enns B, Min JE, Behrends C, Del Rio C, Dombrowski JC, Feaster DJ, Gebo KA, Golden M, Marshall BD, Metsch LR, Schackman BR, Shoptaw S, Strathdee SA, Nosyk B. The impact of localized implementation strategies: modeling the influence of intervention scale and sustainability on the cost-effectiveness of HIV prevention programs across six U.S. cities. *AIDS*. 2020;34(3):447-458.
27. Nosyk B, **Zang X**, Krebs E, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Golden M, Marshall BD, Mehta SH. Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities. *Clinical Infectious Diseases*. 2019 Nov 27;69(12):2195-8.
28. **Zang X**, Zhang M, Wei S, Tang W, Jiang S. Impact of public hospital pricing reform on medical expenditure structure in Jiangsu, China: a synthetic control analysis. *BMC Health Services Research*. 2019 Dec;19(1):512.
29. **Zang X**, Krebs E, Wang L, Marshall BD, Granich R, Schackman BR, Montaner JS, Nosyk B. Structural design and data requirements for simulation modelling in HIV/AIDS: a narrative review. *Pharmacoeconomics*. 2019 Oct;37(10):1219-39.
30. Krebs E, Enns B, Wang L, **Zang X**, Panagiotoglou D, Del Rio C, Dombrowski J, Feaster DJ, Golden M, Granich R, Marshall BD. Developing a dynamic HIV transmission model for 6 US cities: An evidence synthesis. *PloS one*. 2019;14(5).
31. Nosyk B, Min JE, **Zang X**, Feaster DJ, Metsch L, Marshall BD, Rio CD, Granich R, Schackman BR, Montaner JS. Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic. *Journal of the International Association of Providers of AIDS Care (JIAPAC)*. 2019 Jan 21;18:2325958218821962.
32. Nosyk B, Min JE, Krebs E, **Zang X**, Compton M, Gustafson R, Barrios R, Montaner JS. The cost-effectiveness of human immunodeficiency virus testing and treatment engagement initiatives in British Columbia, Canada: 2011–2013. *Clinical Infectious Diseases*. 2018 Feb 15;66(5):765-77.
33. Zhang S, Jiang S, **Zang X**. A promising measure to prevent HPV-positive oral squamous cell carcinoma. *Infection International*. 2017 Nov 28;6(1):30-1.
34. Wang L, Min JE, **Zang X**, Sereda P, Harrigan RP, Montaner JS, Nosyk B. Characterizing Human

immunodeficiency virus antiretroviral therapy interruption and resulting disease progression using population-level data in British Columbia, 1996–2015. *Clinical Infectious Diseases*. 2017 Oct 16;65(9):1496-503.

35. Nosyk B, **Zang X**, Min JE, Krebs E, Lima VD, Milloy MJ, Shoveller J, Barrios R, Harrigan PR, Kerr T, Wood E. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study. *The Lancet HIV*. 2017 Jul 1;4(7):e303-10.
36. **Zang X**, Tang H, Min JE, Gu D, Montaner JS, Wu Z, Nosyk B. Cost-effectiveness of the ‘One4All’ HIV linkage intervention in Guangxi Zhuang autonomous region, China. *PloS one*. 2016 Nov 28;11(11):e0167308.

Work Under Review

Weiner J, Piske M, Enns B, Krebs E, **Zang X**, Nosyk B, Meisel Z. Translating and Disseminating a Localized Economic Model to Support Implementation of the ‘Ending the HIV Epidemic’ Initiative to Public Health Policymakers. [2nd review, *Evidence & Policy*]

Enns B, Krebs E, **Zang X**, Del Rio C, Goedel WC, Marshall BD, Pandya A, Rosen-Metsch L, Schackman BR, Tookes H, Nosyk B. Estimating the budgetary impact of combination implementation strategies towards Ending the HIV Epidemic in Six US Cities. [Submitted, *Journal of the International AIDS Society*]

Zang X, Walley AY, Chatterjee A, Morgan JR, Murphy SM, Linas BP, Nolen, S, Schackman BR, Marshall BDL. Examining the disparate impacts of the COVID-19 pandemic on opioid overdose fatalities and community-based naloxone access across racial/ethnic groups: An interrupted time series analysis in Massachusetts, USA. [Submitted, *Addiction*]

Reports

Chambers LC, Hollowell BD, Scagos RP, Fuchs N, Whitrap D, Rind DM, Hansen RN, Guzauskas GF, Marshall BD, **Zang X**. Harm Reduction Centers Cost Benefit Analysis. Report prepared for *Rhode Island Department of Health*. 2021.

Ti L, Kraiden M, Nosyk B, Socias E, Hayashi K, Harrigan R, Barrios R, Parent S, **Zang X**, Shoveller JA, Hull M, Ramji A, Montaner JS. Evidence Review and Recommendations for Hepatitis B Testing in British Columbia. Report prepared for *British Columbia Ministry of Health*. 2017.

Ti L, Kraiden M, Nosyk B, Socias E, Hayashi K, Harrigan R, Barrios R, Parent S, **Zang X**, Shoveller JA, Hull M, Ramji A, Montaner JS. Evidence Review and Recommendations for Hepatitis C Testing in British Columbia. Report prepared for *British Columbia Ministry of Health*. 2017.

Research Grants

Improving health equity and naloxone access among people at risk for opioid overdose: a distributional cost-effectiveness analysis of community-based naloxone distribution strategies

Role: Principal Investigator

Funder: National Institute on Drug Abuse (CHERISH Pilot Grant)

Project Period: May 1st, 2021 – April 30th, 2022

Project Identifier: P30DA040500

Total Amount: \$4,000

Description: To examine racial/ethnic disparities in access to naloxone among people at risk for opioid overdose in Massachusetts. A distributional cost-effectiveness analysis framework will be used to assess distributional health impacts and cost-effectiveness of current community-based naloxone distribution strategies and alternative targeted interventions focusing on reducing racial/ethnic health disparities.

Localized economic modeling to support implementation of the Ending the HIV Epidemic initiative

Role: Co-investigator

Funder: National Institute on Drug Abuse

Project Period: Sep 30th, 2021 – Aug 31st, 2026

Project Identifier: 2R01DA041747

Total Amount: \$2,732,983

Description: To establish a decision analytical modeling platform that considers all strategies relevant to communities and decision-makers in ‘Ending the HIV Epidemic’ (EHE)-targeted jurisdictions, acknowledges COVID-19-related disruptions in access to services, and integrates new evidence as it emerges. As a renewal project, it will expand the reach and impact of our previous work, advance our efforts on identifying strategies to address the inequities in healthcare access in HIV prevention and treatment, and ultimately reach the ambitious goals of the EHE initiative by 2030.

Prevention and rescue of fentanyl and other opioid overdoses using optimized naloxone distribution strategies (PROFOUND)

Role: Co-investigator

Funder: National Institute on Drug Abuse

Project Period: May 15th, 2019 – February 29th, 2024

Project Identifier: U01-DA047408

Total Amount: \$3,491,173

Description: To address the opioid crisis in this study we will estimate the impact of alternative strategies for community and pharmacy distribution of naloxone on minimizing overdose fatalities and optimizing allocation of available resources in these locations.

Presentations

Conference Oral Presentations:

Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum: A contrast of six US cities. *Society for Medical Decision Making (SMDM), 43rd North American Meeting*, Virtual meeting (October 2021)

The impact of syringe services program closure on the risk of rebound HIV outbreaks among people who inject drugs: A modeling study. *International Network on Hepatitis in Substance Users (INHSU)*, Virtual meeting (October 2021)

Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. *Society for Medical Decision Making (SMDM), 42nd North American Meeting*, Virtual meeting (October 2020)

Evidence synthesis and data needs: One team’s perspective. Workshop for *Economic modeling to inform the public health response to opioid use disorder* (at the 41st SMDM Meeting), Portland, USA (October 2019)

Estimating costs of implementation, delivery and sustainment for evidence-based HIV/AIDS interventions in the United States. *Fast-Track Cities 2019*. London, UK (September 2019)

Development and calibration of a dynamic HIV transmission model for 6 US cities: building a framework for model-based health economic evaluation. *11th Forum of Asia Huaxia Pharmacoeconomics and Health Technology Assessment*, Nanjing, China (June 2019)

- **Best Paper**

Development and calibration of a dynamic HIV transmission model for six US cities. 9th Vancouver Health Economics Methodology Meeting, Vancouver, Canada (June 2019)

- **Best Student Paper**

Impact of pricing reform for drug and medical service of public hospitals on medical expenditure structure in Jiangsu, China: a synthetic control analysis. 2018 Healthcare Management Forum for Young Scholars, Guangzhou, China (November 2018)

Conference Poster Presentations:

Comparing projected fatal overdose outcomes and costs of strategies to expand naloxone distribution: A modeling study of community-based distribution in Rhode Island. Society for Medical Decision Making (SMDM), 44th North American Meeting, Seattle, WA (October 2022)

Comparing projected fatal overdose outcomes and costs of strategies to expand community-based distribution of naloxone in Rhode Island. The 13th National Harm Reduction Conference, San Juan, Puerto Rico (October 2022)

Development of a spatial microsimulation modeling tool for improved naloxone distribution at the community level. Society for Medical Decision Making (SMDM), 43rd North American Meeting, Virtual meeting (October 2021)

Development and calibration of a dynamic HIV transmission model for six US cities. Society for Medical Decision Making (SMDM), 41st North American Meeting, Portland, OR (October 2019)

- **Lee. B. Lusted Award Finalist**

A preamble to ending the HVI epidemic in the United States: Modeled status quo projections for new HIV diagnoses in six US cities. Fast-Track Cities 2019, London, UK (September 2019)

The status quo won't suffice: modeled projections of the HIV/AIDS epidemic across 6 US cities. 10th International AIDS Society (IAS) Conference on HIV Science, Mexico City, Mexico (July 2019)

Cost-effectiveness of the 'One4All' HIV linkage intervention in Guangxi Zhuang Autonomous Region, China. Society for Medical Decision Making (SMDM), 38th North American Meeting, Vancouver, Canada (October 2016)

- **Lee. B. Lusted Award Finalist**

Cost-effectiveness of the 'One4All' HIV linkage intervention in Guangxi Zhuang Autonomous Region, China. 7th Vancouver Health Economics Methodology Meeting, Vancouver, Canada (June 2016)

Academic presentations

Modeling localized combinational implementation strategies to achieve the Ending the HIV Epidemic goals. McGill Summer Institute in Global Health program. Virtual meeting (June, 2022)

Prevention and Rescue of Fentanyl Overdose Using Optimized Naloxone Distribution Strategies (PROFOUND) Project Forum. Webinar (January, 2022)

Localized economic modelling to optimize public health strategies for HIV treatment and prevention. Mathematical modelling of HIV and other STI in Gay, Bisexual and other Men who have Sex with Men Workshop, BCCDC, Vancouver, Canada (April 2018)

Media Coverage of Research

Suspending syringe services programs will result in an increase in HIV infections. [HIV News from NIDA](#). March 2022

Brown study shows suspending syringe services programs will lead to an increase in HIV infections. [Indiana News](#). March 2022

Study Projects HIV Surge After Scott County Syringe Program Closure. [Filter](#). March 2022

Brown study shows suspending syringe services programs would lead to increase in HIV infections. [The Brown Daily Herald](#). March 2022

Closing syringe programs will lead to more HIV infections. [Futurity](#). February 2022.

Suspending syringe services programs will result in an increase of HIV infections, study finds. [ScienceDaily](#); [Medical Press](#); [News from Brown](#). February 2022.

Economic Modeling Shows Optimal HIV-Reduction Interventions Depend on the Location. [NIDA Notes](#). June, 2021.

Teaching Experience

Graduate Teaching Assistant, Simon Fraser University, British Columbia, Canada 2016, 2017, 2018, 2019

Course: *Principles of Epidemiology for Public Health* - HSCI 801 (graduate)

Class size: 34-49

Responsibilities: Led two-hour tutorial every week on supplementary lecture materials, discussion on reading materials, and in-class exercises, wrote exam questions, graded exams and term paper assignments.

Graduate Teaching Assistant, Simon Fraser University, British Columbia, Canada 2017, 2018, 2019

Course: *Health Services Research* - HSCI 416 (undergraduate)

Class size: 8-12

Responsibilities: Led one-hour lab every week teaching programming with SAS software, assisted designing course term project, provided guidance on student's final project, graded term paper assignments.

Graduate Teaching Assistant, Simon Fraser University, British Columbia, Canada 2016

Course: *Exploratory Data Analysis* - HSCI 410 (undergraduate)

Class size: 28

Responsibilities: Held office hours, provided technical assistance for students in R programming, proctored and graded exams.

Graduate Teaching Assistant, Simon Fraser University, British Columbia, Canada 2015

Course: *Perspectives in Health Informatics* - HSCI 472 (undergraduate)

Class size: 38

Responsibilities: Held office hours, proctored and graded exams.

Guest Lecturer, Simon Fraser University, British Columbia, Canada March 2017

Course: *Health Services Research*

Title: Health Economic Evaluation in HIV/AIDS

Guest Lecturer, Simon Fraser University, British Columbia, Canada October 2015

Course: *Perspectives in Health Informatics*

Title: Study on Diabetes-Depression Care management Adoption Trial (DCAT): The Application of Telephonic Monitoring System and Implications for Health Informatics

Honours, Awards & Certificates

- *Graduate Fellowship*, Simon Fraser University (\$3,250) 2020 Spring
- *Graduate Fellowship*, Simon Fraser University (\$3,250) 2019 Fall
- *Presidents PhD Scholarship*, Simon Fraser University (\$6,500) 2019 Spring

- *Travel and Minor Research Award*, Simon Fraser University (\$1,000) 2019 Spring
- *Graduate Fellowship*, Simon Fraser University (\$3,250) 2018 Fall
- *KEY Big Data Graduate Scholarship*, Simon Fraser University (\$6,500) 2018 Summer
- *Graduate Fellowship*, Simon Fraser University (\$6,500) 2018 Spring
- *Graduate Fellowship*, Simon Fraser University (\$6,500) 2017 Fall
- *Graduate Fellowship-special allocation*, Simon Fraser University (\$6,500) 2017 Spring
- *Graduate Fellowship*, Simon Fraser University (\$3,250) 2017 Spring
- SAP Global Certification – Associate Business Foundation & Integration with SAP ERP 6.0 EHP5 2014
- *3rd Place Prize & Award for Excellence*, Transport Science & Tech Contest, China 2012
- *School's Transportation Scholarship*, Southeast University, China (¥1,000) 2011
- National Computer Rank Examination Certificate (Grade 2, C++), China 2010

Work Experience

Postdoctoral Research Associate, Department of Epidemiology, Brown University, RI, USA 03/2020-Present

Research Assistant, British Columbia Centre for Excellence in HIV/AIDS, BC, Canada 09/2015-02/2020

Professional Memberships

- Member, *Society for Medical Decision Making (SMDM)*
- Member, *International AIDS Society (IAS)*

Academic Service

Peer reviewer for:

- BMC Health Services Research
- BMC Public Health
- BMJ Open
- International Journal of Drug Policy
- International Journal of Health Policy and Management
- Journal of Addiction Medicine
- Journal of Infectious Diseases
- Journal of Public Health
- PloS one
- Society for Medical Decision Making (conference abstracts)
- The Lancet Public Health
- Value in Health
- Value in Health, Regional Issues